Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Bioactivity of Inhaled Nebulized RNS60
NCT02490865Phase 1Completed
- Sponsor
- Revalesio Corporation
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RNS60 in inflammation and muscle injury, sponsored by Revalesio Corporation. Primary endpoint: Creatine Kinase. Started Jul 2015; status: completed.
02
Drugs
RNS60
03
Conditions
inflammationmuscle injury
Beyond the preview
Go deeper on NCT02490865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490865.